Fuan Pharmaceutical (Group) Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Fuan Pharmaceutical (Group) Co., Ltd. carries a market capitalization of 4.51B, placing it among publicly traded companies globally. Its enterprise value stands at 4.79B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.51B |
| Enterprise Value | 4.79B |
Share Statistics
Fuan Pharmaceutical (Group) Co., Ltd. currently has 1.19B shares outstanding.
| Shares Outstanding | 1.19B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Fuan Pharmaceutical (Group) Co., Ltd. trades at a trailing price-to-earnings ratio of 27.58. The price-to-sales ratio is 2.59, and the price-to-book ratio stands at 2.33.
| PE Ratio | 27.58 |
| PS Ratio | 2.59 |
| PB Ratio | 2.33 |
| P/TBV Ratio | 1.34 |
| P/FCF Ratio | 24.59 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Fuan Pharmaceutical (Group) Co., Ltd. trades at an EV/EBITDA multiple of 27.68 and an EV/FCF ratio of 21.89. The EV/Sales ratio of 2.55 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 27.68 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.55 |
| EV / EBITDA | 27.68 |
| EV / EBIT | 27.68 |
| EV / FCF | 21.89 |
Financial Position
Fuan Pharmaceutical (Group) Co., Ltd. maintains a current ratio of 1.91, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 20.50, indicating elevated leverage, while an interest coverage ratio of 7.83 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.91 |
| Quick Ratio | 0.91 |
| Debt / Equity | 20.50 |
| Debt / EBITDA | 5.25 |
| Interest Coverage | 7.83 |
Financial Efficiency
Fuan Pharmaceutical (Group) Co., Ltd. posts a return on equity of 8.63 and a return on invested capital of 3.16.
| Return on Equity (ROE) | 8.63 |
| Return on Assets (ROA) | 2.94 |
| Return on Invested Capital (ROIC) | 3.16 |
| Return on Capital Employed (ROCE) | 6.94 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.37 |
Taxes
Over the trailing twelve months, Fuan Pharmaceutical (Group) Co., Ltd. has paid 9.40M in income taxes, reflecting an effective tax rate of 5.09.
| Income Tax | 9.40M |
| Effective Tax Rate | 5.09 |
Stock Price Statistics
Fuan Pharmaceutical (Group) Co., Ltd.'s stock has declined approximately -11.4486% over the past 52 weeks. The 50-day moving average sits at 4.08, while the 200-day moving average is 4.38.
| Beta (5Y) | N/A |
| 52-Week Price Change | -11.4486% |
| 50-Day Moving Average | 4.08 |
| 200-Day Moving Average | 4.38 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Fuan Pharmaceutical (Group) Co., Ltd. generated 1.88B in revenue and converted that into 176.48M in net income, yielding earnings per share of 0.15. EBITDA reached 173.19M, while operating income came in at 173.19M.
| Revenue | 1.88B |
| Gross Profit | 843.55M |
| Operating Income | 173.19M |
| Pretax Income | 184.76M |
| Net Income | 176.48M |
| EBITDA | 173.19M |
| EBIT | 173.19M |
| Earnings Per Share (EPS) | 0.15 |
Balance Sheet
Fuan Pharmaceutical (Group) Co., Ltd. holds 986.18M in cash and equivalents against 909.73M in total debt, resulting in a net debt position of -116.59M. Total book value stands at 2.09B, with working capital of 990.88M providing operational flexibility.
| Cash & Cash Equivalents | 986.18M |
| Total Debt | 909.73M |
| Net Debt | -116.59M |
| Equity (Book Value) | 2.09B |
| Book Value Per Share | 1.82 |
| Working Capital | 990.88M |
Cash Flow
After subtracting -197.96M in capital expenditures, free cash flow totaled -197.96M - equivalent to -0.17 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -197.96M |
| Free Cash Flow | -197.96M |
| FCF Per Share | -0.17 |
Margins
Fuan Pharmaceutical (Group) Co., Ltd. operates with a gross margin of 44.89, reflecting its pricing power and cost economics. The operating margin of 9.22 and net profit margin of 9.39 provide insight into operational efficiency.
| Gross Margin | 44.89 |
| Operating Margin | 9.22 |
| Pretax Margin | 9.83 |
| Profit Margin | 9.39 |
| EBITDA Margin | 9.22 |
Dividends & Yields
The company's payout ratio of 46.50 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.07 |
| Dividend Yield | N/A |
| Payout Ratio | 46.50 |
| Shareholder Yield | -2.21 |
| FCF Yield | 4.07 |
Stock Splits
Fuan Pharmaceutical (Group) Co., Ltd.'s most recent stock split took place on May 10, 2017 with a 1:3 split ratio.
| Last Split Date | 5/10/2017 |
| Split Ratio | 1:3 |
Scores
Fuan Pharmaceutical (Group) Co., Ltd. posts an Altman Z-Score of 2.82, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.82 |